Who it's for
Pending FDA approval. Phase 3 trial populations were adults with obesity (BMI ≥30) and adults with type 2 diabetes. Likely indicated audience at launch will mirror Wegovy and Zepbound criteria for the obesity indication.
What the trials show
Orforglipron's registration trial was ATTAIN-1 (NEJM, 2025). At 72 weeks at the maximum dose, mean weight loss was 12.4% (10.5 percentage points greater than placebo). 80.0% of patients lost at least 5% of body weight; 36.0% lost at least 15%. Real-world results vary; trial patients are typically more adherent and more closely managed than typical telehealth patients.
Dose schedule
Dose levels: 3mg, 12mg, 36mg. Standard practice is to titrate up monthly, holding at any tolerated dose. Maximum dose is 36mg daily (in trials); many patients reach goal weight at sub-maximum doses and stay there.
What it costs in 2026
| Retail cash (no insurance, no DTC) | Not yet on market |
| Manufacturer DTC (cash-pay direct) | Lilly has indicated competitive cash-pay pricing planned via LillyDirect on launch |
| With insurance + prior authorization | Pending FDA approval |
| Compounded version (503A pharmacy) | Found's Foundayo program prepares compounded orforglipron via 503A pharmacies pre-approval; carries the highest regulatory exposure in compounded GLP-1 because the molecule is not yet FDA-approved as a drug product |
Telehealth programs add a membership fee on top of the medication cost (typically $40-$200/mo). For all-in monthly costs by program, see the chart.
Common side effects
The most commonly reported side effects in the registration trial:
- nausea (25-30% in trials)
- diarrhea (18-22%)
- vomiting (10-14%)
- constipation (10%)
- abdominal discomfort (8%)
Boxed warning: Pending labeling. As a GLP-1 receptor agonist, expected to carry the same class warning as semaglutide and tirzepatide regarding thyroid C-cell tumor risk based on rodent data.
How Orforglipron differs from related drugs
First oral non-peptide GLP-1. If approved, expected to be cheaper to manufacture and ship than injectable peptides, which could meaningfully lower the all-in cost of GLP-1 therapy. Direct trial comparison to injectable semaglutide and tirzepatide is forthcoming.
Compounded orforglipron (Found's Foundayo program)
Compounded orforglipron (Found's Foundayo program) is the same active molecule prepared by a 503A pharmacy under prescription rather than manufactured under FDA new-drug approval as Orforglipron. Cash-pay savings versus branded Orforglipron are typically 50-80%, but the regulatory environment has tightened. Not on shortage list (not yet approved). Compounded orforglipron pre-approval carries higher regulatory exposure than compounded semaglutide or tirzepatide. For the comparison, see compounded vs FDA-approved semaglutide.
Programs that prescribe Orforglipron
These programs in our chart prescribe Orforglipron (with insurance coverage where applicable, or as a cash-pay option). Ranked by overall score.
Editorial disclosure
GLP Chart is an editorial comparison site. We do not dispense, prescribe, or fulfill medications. Talk to a licensed clinician about whether Orforglipron is appropriate for you. Pricing reflects publicly verified rates as of 12 May 2026; verify with the manufacturer or your prescriber before committing.